MedTrace Logo

Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma

NCT00703664 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2018-08-07

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well bortezomib and vorinostat work in treating patients with recurrent mantle cell lymphoma or recurrent and/or refractory diffuse large B-cell lymphoma. Bortezomib and vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Conditions

  • Recurrent Mantle Cell Lymphoma
  • Recurrent Non-Hodgkin Lymphoma

Interventions

DRUG

Bortezomib

Bortezomib: 1.3 mg/m\^2/d IV days 1, 4, 8, and 11.

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Vorinostat

Vorinostat: 400 mg (total daily dose as a single dose) days 1-5 and 8-12.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Beata Holkova · Massey Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-09
Primary Completion
2017-12-01
Completion
2017-12-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00703664 on ClinicalTrials.gov